



Patent Docket P0987R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Martin M. Bednar et al.
Serial No.: 08/788,800
Filed: January 22, 1997
For: ANTI-CD18 ANTIBODIES IN STROKE

Group Art Unit: 1806

Examiner: P. Gambel

CERTIFICATE OF MAILING
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on

March 2, 1998

Sandra K. T. Sullivan
Sandra K. T. Sullivan

AMENDMENT UNDER 37 C.F.R. §1.111

RECEIVED

MAR - 9 1998

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated October 2, 1997, the period for response having been extended as a result of the enclosed Petition for a two month Extension of Time and requisite fee, Applicants respectfully request reconsideration of the above-identified application in view of the following amendments and remarks.

MATRIX CUSTOMER
SERVICE CENTER

IN THE SPECIFICATION:

On page 13, line 12, please insert --(SEQ ID NO:11)-- at the end of the sequence and before the period.

IN THE CLAIMS:

In claim 1, before "mammal" please insert --human--

In claim 10, line 2, please replace "mins" with --minutes--

11. (Amended) The method of claim 1 wherein the anti-CD18 antibody is humanized H52 antibody comprising heavy chain sequence of SEQ ID NO:10 and light chain sequence of SEQ ID NO:11.

Please cancel claims 13 and 14 without prejudice or disclaimer of the subject matter therein.

In claim 15, line 7, please delete "antagonist".